WEBVTT 00:00:00.299 --> 00:00:02.709 A patient hears that her kidney blood test is fine. 00:00:02.987 --> 00:00:05.376 But the urine albumin test has never been done. 00:00:05.589 --> 00:00:09.703 What does that leave unanswered? Welcome to HEART RESERVE Clinical Conversations. 00:00:09.976 --> 00:00:13.876 I’m Lisa Zahakos, a physician assistant and founder of HEART RESERVE. 00:00:14.149 --> 00:00:18.458 In this episode, we’ll follow Denise with an incomplete assessment, Rosa with 00:00:18.544 --> 00:00:22.768 residual kidney and cardiovascular risk, and Carol with a safety result that 00:00:22.810 --> 00:00:26.850 changes the next step. These are fictional teaching cases for clinicians. 00:00:27.177 --> 00:00:30.078 You can listen straight through, or use the chapters to return to 00:00:30.121 --> 00:00:33.108 a case. I’ll ask you to consider a few decisions and then 00:00:33.193 --> 00:00:37.203 walk through the reasoning. The activity page has the objectives, references and 00:00:37.246 --> 00:00:40.204 online questions. Let’s work through the first case. 00:00:40.460 --> 00:00:45.239 Denise, 49, is a fictional patient with type 2 diabetes diagnosed three 00:00:45.324 --> 00:00:48.460 years ago after a remote history of gestational diabetes. 00:00:48.738 --> 00:00:50.715 She works shifts and helps care for her mother. 00:00:50.901 --> 00:00:55.764 Today her A one C is 6.7 percent, blood pressure is 132/80 00:00:55.807 --> 00:00:59.860 millimeters of mercury, and E G F R is 78 milliliters per 00:00:59.903 --> 00:01:02.131 minute per one point seven three square meters. 00:01:02.523 --> 00:01:07.665 The chart contains several metabolic panels but no quantitative urine albumin-to-creatinine ratio, 00:01:07.771 --> 00:01:10.331 or U A C R, during the past year. 00:01:10.673 --> 00:01:14.407 She says, “I thought the blood test checked my kidneys.” The immediate 00:01:14.449 --> 00:01:19.655 teaching problem is incomplete assessment. Her reassuring glucose result and preserved filtration 00:01:19.953 --> 00:01:24.143 should not close the visit. Before going further, consider what is missing. 00:01:24.449 --> 00:01:28.460 Denise's pregnancy history belongs in the longitudinal health record, but this encounter 00:01:28.630 --> 00:01:30.508 is about the kidney-to-heart connection now. 00:01:30.679 --> 00:01:35.350 Two measurements answer different questions. E G F R estimates filtration; U 00:01:35.435 --> 00:01:38.422 A C R measures albumin relative to urine creatinine. 00:01:38.678 --> 00:01:43.670 The 2026 American Diabetes Association standard calls for both at least annually 00:01:43.841 --> 00:01:45.744 in all people with type 2 diabetes. 00:01:46.027 --> 00:01:50.208 In established chronic kidney disease, monitoring becomes more frequent according to risk. 00:01:50.464 --> 00:01:54.091 A normal-looking filtration estimate cannot substitute for the urine measure. 00:01:54.432 --> 00:01:57.280 Use the first result to decide what needs verification. 00:01:57.654 --> 00:02:01.280 A U A C R below 30 milligrams per gram is category 00:02:01.408 --> 00:02:06.848 A1; 30 to 299 is A2; 300 or more is A3. 00:02:07.040 --> 00:02:10.377 Interpret these with the filtration category and clinical setting. 00:02:10.685 --> 00:02:14.568 A single abnormal value does not by itself establish chronic disease. 00:02:14.824 --> 00:02:19.304 chronic kidney disease requires an abnormality of kidney structure or function lasting 00:02:19.389 --> 00:02:22.742 at least three months. Do not apply a chronic label to an 00:02:22.785 --> 00:02:25.153 acute change without evaluating what happened. 00:02:25.515 --> 00:02:29.867 The result comes back. Denise's U A C R is 86 milligrams 00:02:29.953 --> 00:02:33.366 per gram. The nurse learns that she had urinary burning when the 00:02:33.409 --> 00:02:36.540 sample was taken. The next task is to assess and treat the 00:02:36.582 --> 00:02:40.486 symptomatic problem as clinically indicated, then arrange confirmation. 00:02:40.806 --> 00:02:46.780 Infection, recent strenuous exercise, menstruation and other transient influences can raise urinary 00:02:46.908 --> 00:02:52.681 albumin. American Diabetes Association describes confirmation with two abnormal samples among three 00:02:52.767 --> 00:02:54.623 collected over three to six months. 00:02:54.986 --> 00:02:58.527 The clinician must also establish chronicity and interpret the whole record. 00:02:58.868 --> 00:03:02.596 Here is the decision. Denise has E G F R 78 and 00:03:02.638 --> 00:03:04.110 no recorded U A C R. 00:03:04.260 --> 00:03:05.924 What should the team do next? 00:03:06.265 --> 00:03:08.477 Pause here if you would like a moment to think it through. 00:03:08.768 --> 00:03:11.798 The best next step in this case is: Complete the urine albumin 00:03:11.840 --> 00:03:13.867 assessment and review both kidney measures. 00:03:14.102 --> 00:03:17.643 Both measures are needed; neither A one C nor past pregnancy history 00:03:17.899 --> 00:03:21.245 substitutes for the missing assessment. This does not mean ignoring the result 00:03:21.374 --> 00:03:25.469 for six months. Confirm that Denise receives the message, determine an appropriate 00:03:25.512 --> 00:03:29.491 repeat collection date and document the clinician responsible for interpreting it. 00:03:29.715 --> 00:03:33.726 If she has acute illness, a rapid deterioration in renal function or 00:03:33.768 --> 00:03:37.736 other concerning findings, a routine confirmation schedule is inadequate. 00:03:37.992 --> 00:03:41.968 Clinical urgency always comes first. Make the missing test easy to complete. 00:03:42.317 --> 00:03:45.794 Denise can attend laboratory appointments only before an early shift. 00:03:46.072 --> 00:03:49.948 Ask whether a same-site collection or a coordinated morning visit is feasible. 00:03:50.240 --> 00:03:53.781 Explain the purpose in plain language: “The blood test and urine test 00:03:53.952 --> 00:03:55.744 tell us different parts of the kidney story. 00:03:56.000 --> 00:03:59.140 We need both before we can put the results together.” This original 00:03:59.396 --> 00:04:04.407 counseling example supports understanding without promising that an abnormal result will disappear. 00:04:04.639 --> 00:04:07.796 A practical office workflow is to check for both results before a 00:04:07.839 --> 00:04:11.935 diabetes review, flag an uncompleted order, and route the result to a 00:04:11.978 --> 00:04:17.207 named inbox owner. These are proposed implementation choices, not measured results of 00:04:17.250 --> 00:04:20.525 this activity. The team should adapt them to its own staffing and 00:04:20.567 --> 00:04:24.621 laboratory arrangements. A new electronic order is not success if the sample 00:04:24.749 --> 00:04:27.726 is never collected. Follow-up over the next six months. 00:04:28.263 --> 00:04:31.342 In the fictional follow-up, the infection has resolved. 00:04:31.562 --> 00:04:35.616 Two properly collected U A C R samples are 74 and 71 00:04:35.658 --> 00:04:39.498 milligrams per gram, obtained more than three months apart within a six-month 00:04:39.584 --> 00:04:43.808 confirmation period, with no identified transient cause and stable E G F 00:04:43.893 --> 00:04:48.814 R. Denise now needs evaluation of cause, risk and management, rather than 00:04:48.857 --> 00:04:53.550 a message saying only “mildly abnormal.” The clinical team reviews blood pressure, 00:04:53.763 --> 00:04:57.887 medications, cardiovascular risk, symptoms and the trajectory. 00:04:58.171 --> 00:05:02.736 Diabetes can coexist with other kidney disease; atypical features should not automatically 00:05:02.907 --> 00:05:07.292 be attributed to diabetes. The transfer lesson is a sequence: identify the 00:05:07.335 --> 00:05:12.391 missing measurement, interpret the result, establish persistence and ensure someone acts. 00:05:12.753 --> 00:05:16.349 Notice the difference between the medical question, what does the result mean?, 00:05:16.568 --> 00:05:20.280 and the operational question, who will make sure it is reviewed? 00:05:20.664 --> 00:05:23.608 Both matter to a woman whose health information is spread across several 00:05:23.778 --> 00:05:27.904 clinicians. Here is the decision. Her first U A C R of 00:05:27.947 --> 00:05:31.488 86 milligrams per gram was collected during urinary symptoms. 00:05:31.787 --> 00:05:33.600 Which plan best closes this step? 00:05:33.877 --> 00:05:36.045 Pause here if you would like a moment to think it through. 00:05:36.292 --> 00:05:40.004 The best next step in this case is: Assess the symptomatic problem, 00:05:40.260 --> 00:05:43.481 arrange confirmation and name the result-reviewing clinician. 00:05:43.716 --> 00:05:48.378 Interpret the clinical context, establish persistence and make the result actionable. 00:05:48.688 --> 00:05:50.544 Here is what to carry into the next visit. 00:05:50.907 --> 00:05:54.363 Find the E G F R and U A C R, with 00:05:54.448 --> 00:05:58.267 dates. Check transient influences and establish chronicity. 00:05:58.672 --> 00:06:01.169 Name the clinician who will review the repeat result. 00:06:01.703 --> 00:06:06.353 Now let’s change the situation. Rosa, 61, is a fictional woman with 00:06:06.439 --> 00:06:10.063 type 2 diabetes, obesity and confirmed chronic kidney disease. 00:06:10.273 --> 00:06:13.089 Over six months her E G F R has remained near 46 00:06:13.175 --> 00:06:16.673 milliliters per minute per one point seven three square meters and U 00:06:16.716 --> 00:06:19.468 A C R near 420 milligrams per gram. 00:06:19.916 --> 00:06:22.695 Potassium is 4.6 milliequivalents per liter. 00:06:22.956 --> 00:06:27.991 She takes metformin and a tolerated angiotensin receptor blocker; medication reconciliation finds 00:06:28.119 --> 00:06:31.234 no S G L T 2 inhibitor, G L P 1 receptor 00:06:31.276 --> 00:06:35.500 agonist or finerenone. Her A one C is 6.5 percent, at her 00:06:35.543 --> 00:06:40.206 individualized goal. She asks, “Why add another medicine when the diabetes number 00:06:40.377 --> 00:06:42.958 is good?” Rosa's question is reasonable. 00:06:43.278 --> 00:06:46.917 Begin by explaining the problem the proposed treatment is intended to address. 00:06:47.185 --> 00:06:50.982 The decision is about kidney disease progression and cardiovascular events as well 00:06:51.025 --> 00:06:54.652 as glucose control. It is not an automatic instruction to add every 00:06:54.780 --> 00:06:56.372 available drug on the same day. 00:06:56.598 --> 00:07:02.742 Establish her current regimen, symptoms, volume status, comorbidities, previous adverse effects, medication 00:07:02.913 --> 00:07:05.601 access and preferences before selecting a plan. 00:07:05.942 --> 00:07:08.322 Separate the glucose goal from organ protection. 00:07:08.654 --> 00:07:12.964 Published guidance recommends an S G L T 2 inhibitor with demonstrated 00:07:13.092 --> 00:07:17.223 benefit for appropriate people with type 2 diabetes and chronic kidney disease, 00:07:17.514 --> 00:07:21.141 with initiation generally supported from E G F R 20 milliliters per 00:07:21.183 --> 00:07:24.682 minute per one point seven three square meters; the exact product label 00:07:24.810 --> 00:07:28.906 and indication still matter. G L P 1 therapy with demonstrated benefit 00:07:29.034 --> 00:07:33.273 also has a role. The presence of albuminuric chronic kidney disease should 00:07:33.315 --> 00:07:36.596 trigger a broader discussion even when A one C is at target. 00:07:36.932 --> 00:07:41.156 For Rosa, review blood pressure control and whether her angiotensin receptor blocker 00:07:41.242 --> 00:07:46.319 is appropriately optimized and tolerated. An ACE inhibitor and angiotensin receptor blocker 00:07:46.447 --> 00:07:50.775 should not be combined. Check kidney function, potassium and symptoms when these 00:07:50.861 --> 00:07:57.087 therapies are initiated or intensified. Treating lipids, smoking, physical activity, nutrition and 00:07:57.129 --> 00:08:01.054 other cardiovascular risks remains part of comprehensive care; a new drug does 00:08:01.097 --> 00:08:04.395 not replace that work. Review the trial before making the claim. 00:08:04.707 --> 00:08:10.104 EMPA-KIDNEY enrolled a broad chronic kidney disease population, including people without diabetes. 00:08:10.382 --> 00:08:14.808 Its primary outcome combined kidney disease progression with cardiovascular death. 00:08:15.138 --> 00:08:18.551 DAPA C K D also studied chronic kidney disease with and without 00:08:18.765 --> 00:08:23.298 diabetes, but used different entry criteria and a different composite endpoint. 00:08:23.607 --> 00:08:27.874 These trials support treatment decisions in suitable populations; they are not a 00:08:27.916 --> 00:08:29.998 head-to-head comparison of the two medicines. 00:08:30.330 --> 00:08:34.938 FLOW studied once-weekly injectable semaglutide in people with type 2 diabetes and 00:08:34.981 --> 00:08:39.845 chronic kidney disease. Its primary composite included major kidney disease events and 00:08:39.930 --> 00:08:44.725 kidney-related or cardiovascular death. It provides outcomes evidence for the studied regimen 00:08:44.768 --> 00:08:49.014 and population. Do not transfer that result automatically to every G L 00:08:49.014 --> 00:08:52.503 P 1 medicine, formulation or obesity population. 00:08:52.856 --> 00:08:57.763 The current Ozempic injection label includes a chronic kidney disease-related risk-reduction indication 00:08:58.061 --> 00:09:00.259 in adults with type 2 diabetes. 00:09:00.451 --> 00:09:04.698 Here is the decision. Rosa asks why organ-protective treatment is being discussed 00:09:04.869 --> 00:09:06.362 when A one C is at target. 00:09:06.618 --> 00:09:09.263 Which reply is best? Pause here if you would like a moment 00:09:09.391 --> 00:09:12.321 to think it through. The best next step in this case is: 00:09:12.534 --> 00:09:17.569 Kidney and cardiovascular outcomes are separate treatment considerations; review proven benefit and 00:09:17.611 --> 00:09:21.631 individual safety. Explain the clinical goal and match evidence to the person. 00:09:21.939 --> 00:09:25.949 FIDELITY pooled the finerenone outcome trials in type 2 diabetes and chronic 00:09:26.035 --> 00:09:29.811 kidney disease on background renin, angiotensin system blockade. 00:09:30.216 --> 00:09:32.655 It reported cardiovascular and kidney benefits. 00:09:32.962 --> 00:09:37.612 Finerenone therefore enters a discussion about persistent residual risk, together with its 00:09:37.655 --> 00:09:42.007 potassium and kidney-function requirements. It is not simply an interchangeable blood pressure 00:09:42.178 --> 00:09:45.513 tablet. A useful new study is still a specific study. 00:09:45.791 --> 00:09:49.929 CONFIDENCE compared finerenone plus empagliflozin with each alone in people with type 00:09:49.929 --> 00:09:55.625 2 diabetes, chronic kidney disease and albuminuria already receiving renin, angiotensin system 00:09:55.796 --> 00:10:00.148 inhibition. Its primary outcome was relative U A C R change at 00:10:00.190 --> 00:10:04.927 180 days. Combination therapy reduced U A C R more than either 00:10:05.054 --> 00:10:09.176 monotherapy. That is a biomarker finding, not proof from this trial of 00:10:09.219 --> 00:10:12.675 fewer kidney failures or cardiovascular deaths versus each component. 00:10:12.888 --> 00:10:15.704 It can inform a conversation without becoming a claim the study did 00:10:15.747 --> 00:10:20.873 not test. Compare each study’s population, endpoint and clinical implication. 00:10:21.214 --> 00:10:25.182 Ask whether each result answers Rosa’s clinical question, and distinguish a change 00:10:25.310 --> 00:10:28.057 in albuminuria from a reduction in clinical events. 00:10:28.285 --> 00:10:34.131 Shared decisions include practical constraints. Rosa reports recurrent genital yeast infections, worries 00:10:34.216 --> 00:10:38.220 about medication cost and does not want several unexplained changes at once. 00:10:38.554 --> 00:10:41.498 An S G L T 2 discussion includes the risk of genital 00:10:41.669 --> 00:10:47.483 infection, volume depletion, and ketoacidosis, which can occur without marked hyperglycemia. 00:10:47.793 --> 00:10:52.316 She needs individualized sick-day and procedural instructions and a clear route to 00:10:52.358 --> 00:10:57.385 clinical advice. For empagliflozin, the label specifies withholding for at least three 00:10:57.470 --> 00:11:01.886 days, if possible, before surgery or procedures with prolonged fasting. 00:11:02.163 --> 00:11:05.817 Resume according to clinical stability and oral intake guidance. 00:11:06.143 --> 00:11:12.031 If considering injectable semaglutide, review its contraindications, including personal or family medullary 00:11:12.287 --> 00:11:19.483 thyroid carcinoma or multiple endocrine neoplasia type 2, gastrointestinal tolerability, pancreatitis warnings, 00:11:19.809 --> 00:11:23.670 retinopathy context, and dehydration-related renal concerns. 00:11:24.118 --> 00:11:27.830 These are reasons to assess and counsel carefully, not reasons to assume 00:11:27.916 --> 00:11:30.807 all patients face the same balance of benefit and harm. 00:11:31.053 --> 00:11:34.530 Use the current full prescribing information for the complete evaluation. 00:11:34.893 --> 00:11:38.605 The worked communication example is: “Your glucose goal is one part of 00:11:38.647 --> 00:11:41.857 the plan. Your kidney results show another risk we can address. 00:11:42.165 --> 00:11:45.194 Let us compare what each option has been shown to do, what 00:11:45.237 --> 00:11:48.978 might make it difficult for you, and what follow-up it needs.” Discuss 00:11:49.021 --> 00:11:53.757 affordable options and assistance through appropriate channels without steering the clinical decision 00:11:53.970 --> 00:11:58.056 toward a sponsor. Record an agreed next action and review date; the 00:11:58.099 --> 00:12:00.957 vignette alone cannot determine Rosa's final prescription. 00:12:01.341 --> 00:12:04.960 Here is the decision. A colleague describes CONFIDENCE as proof that the 00:12:05.003 --> 00:12:08.181 combination prevents more kidney failures than either drug alone. 00:12:08.459 --> 00:12:10.976 How should you respond? Pause here if you would like a moment 00:12:11.147 --> 00:12:14.220 to think it through. The best next step in this case is: 00:12:14.497 --> 00:12:18.636 Clarify that the primary endpoint was U A C R change, not 00:12:18.721 --> 00:12:24.463 comparative kidney-failure events. Randomization supports the measured comparison; it does not change 00:12:24.548 --> 00:12:26.809 the endpoint into one that was not tested. 00:12:27.108 --> 00:12:28.964 Here is what to carry into the next visit. 00:12:29.284 --> 00:12:32.215 State the organ-risk goal separately from the glucose goal. 00:12:32.459 --> 00:12:35.723 Match population, endpoint, product and indication. 00:12:36.043 --> 00:12:39.878 Discuss safety, cost, preferences and monitoring together. 00:12:40.452 --> 00:12:44.015 For the third case, the follow-up plan becomes especially important. 00:12:44.378 --> 00:12:49.028 Carol, 67, is a fictional woman with type 2 diabetes, hypertension and 00:12:49.071 --> 00:12:53.166 persistent albuminuria. Her E G F R is 38 milliliters per minute 00:12:53.379 --> 00:12:56.536 per one point seven three square meters and U A C R 00:12:56.707 --> 00:13:02.219 is 560 milligrams per gram. A proposed finerenone prescription is awaiting review. 00:13:02.526 --> 00:13:06.109 Today's potassium is 5.3 milliequivalents per liter. 00:13:06.405 --> 00:13:12.144 She takes an angiotensin receptor blocker, sometimes uses an over-the-counter anti-inflammatory medicine, 00:13:12.293 --> 00:13:15.494 and recently began a salt substitute after reading that it might help 00:13:15.579 --> 00:13:19.230 blood pressure. She feels well and has a specialist appointment scheduled in 00:13:19.273 --> 00:13:23.070 eight weeks. The teaching task is to stop the prescription from moving 00:13:23.241 --> 00:13:26.825 ahead without review and to establish who is responsible while the referral 00:13:26.910 --> 00:13:30.132 is pending. Do not infer the cause of the potassium result from 00:13:30.175 --> 00:13:34.975 the vignette. The clinician needs to assess the specimen, trend, symptoms, medications, 00:13:35.295 --> 00:13:40.096 supplements and current health. A severely abnormal result or concerning symptoms would 00:13:40.139 --> 00:13:45.003 change the urgency; this exercise does not provide a universal outpatient hyperkalemia 00:13:45.046 --> 00:13:47.741 protocol. Safety changes the next action. 00:13:48.090 --> 00:13:51.802 The finerenone US label states that treatment should not be initiated if 00:13:51.845 --> 00:13:55.386 potassium is above 5.0 milliequivalents per liter. 00:13:55.728 --> 00:13:58.534 Kidney function also affects eligibility and dosing. 00:13:58.823 --> 00:14:03.474 Review interactions, including strong C Y P 3 A 4 inhibitors, and 00:14:03.516 --> 00:14:08.752 contraindications such as adrenal insufficiency. The label's four-week potassium check after initiation 00:14:09.008 --> 00:14:12.976 does not justify starting in Carol's current situation or waiting four weeks 00:14:13.062 --> 00:14:18.294 to address her existing abnormality. After appropriate assessment and correction, if finerenone 00:14:18.337 --> 00:14:23.030 is selected and initiation criteria are met, arrange potassium monitoring at four 00:14:23.116 --> 00:14:27.530 weeks after starting and after dose adjustment, with subsequent testing as clinically 00:14:27.744 --> 00:14:33.653 indicated. For ACE inhibitor or angiotensin receptor blocker initiation or dose escalation, 00:14:33.973 --> 00:14:38.880 KDIGO recommends checking blood pressure, creatinine and potassium within two to four 00:14:38.922 --> 00:14:41.456 weeks, adjusted to the clinical context. 00:14:41.712 --> 00:14:45.552 These are different medication-specific follow-up decisions; do not replace them with a 00:14:45.595 --> 00:14:50.210 generic annual diabetes visit. The medication list includes what the patient buys. 00:14:50.517 --> 00:14:54.101 Ask Carol to bring or photograph the labels of nonprescription medicines and 00:14:54.143 --> 00:14:59.690 salt substitutes. Some contain potassium, and kidney function and concomitant therapy affect 00:14:59.775 --> 00:15:04.710 the advice. Avoid a blanket instruction either to eliminate every potassium-containing food 00:15:04.924 --> 00:15:07.825 or to use a potassium salt substitute freely. 00:15:08.209 --> 00:15:11.314 Coordinate individualized dietary review when appropriate. 00:15:11.560 --> 00:15:14.760 The purpose is a workable plan based on the actual product and 00:15:14.803 --> 00:15:17.918 laboratory findings, not a generic food restriction. 00:15:18.430 --> 00:15:21.473 Carol explains that she is afraid of “bothering” the office. 00:15:21.871 --> 00:15:24.389 Give her the name of the team handling the next result and 00:15:24.431 --> 00:15:27.717 a specific contact method. Ask what she would do if she develops 00:15:27.844 --> 00:15:32.636 new symptoms, cannot obtain the laboratory test, or receives conflicting instructions. 00:15:33.076 --> 00:15:36.191 Teach-back can reveal that a plan written clearly in the chart was 00:15:36.233 --> 00:15:40.201 not understood at home. These are original examples of care coordination for 00:15:40.244 --> 00:15:43.051 discussion and adaptation. Here is the decision. 00:15:43.383 --> 00:15:46.754 Carol has potassium 5.3 before proposed finerenone. 00:15:46.967 --> 00:15:49.783 What is the next action? Pause here if you would like a 00:15:49.826 --> 00:15:52.497 moment to think it through. The best next step in this case 00:15:52.668 --> 00:15:57.383 is: Do not initiate; clinically assess the result and contributing factors. 00:15:57.617 --> 00:16:02.055 The initiation restriction applies now. Review urgency based on the complete clinical 00:16:02.268 --> 00:16:05.484 situation. Referral does not transfer care automatically. 00:16:05.783 --> 00:16:11.543 Progressively rising albuminuria, falling E G F R, uncertainty about cause, difficult 00:16:11.756 --> 00:16:16.131 electrolyte or blood pressure management, and advanced chronic kidney disease can prompt 00:16:16.260 --> 00:16:22.489 nephrology involvement. Active urinary sediment, rapid deterioration or other atypical findings deserve 00:16:22.574 --> 00:16:26.594 evaluation rather than assuming uncomplicated diabetic kidney disease. 00:16:26.945 --> 00:16:30.870 Determine the appropriate urgency and send the trends and current medication list 00:16:30.998 --> 00:16:34.750 with the referral. The primary team should confirm whether the receiving service 00:16:34.963 --> 00:16:38.368 accepted the referral and whether the appointment timing is appropriate. 00:16:38.615 --> 00:16:43.437 Until responsibilities are explicitly agreed, retain an interim owner for current abnormalities 00:16:43.735 --> 00:16:48.112 and medication decisions. A specialist's name in an electronic order does not 00:16:48.197 --> 00:16:51.696 establish that the specialist has seen the patient, reviewed the result or 00:16:51.781 --> 00:16:54.503 agreed to manage it. A worked follow-up plan. 00:16:55.094 --> 00:17:00.129 For this teaching example, the prescribing clinician pauses the proposed finerenone initiation, 00:17:00.385 --> 00:17:06.017 reviews potassium and contributing factors promptly, determines repeat testing and urgency, and 00:17:06.060 --> 00:17:08.016 communicates the interim plan to Carol. 00:17:08.181 --> 00:17:12.106 The team checks referral acceptance, sends the renal trend and reconciled medication 00:17:12.277 --> 00:17:16.053 list, and records who will respond to results before the specialist visit. 00:17:16.459 --> 00:17:19.497 The final clinical timetable depends on the full assessment. 00:17:19.719 --> 00:17:22.279 Consider how that plan would work in your own setting. 00:17:22.706 --> 00:17:26.118 At a subsequent visit, Carol reports that she understood the test was 00:17:26.162 --> 00:17:28.411 needed but could not find transportation. 00:17:28.741 --> 00:17:32.965 The response should address the barrier and re-evaluate whether delay changes urgency. 00:17:33.221 --> 00:17:35.862 A missed test is not automatically refusal. 00:17:36.114 --> 00:17:40.594 A feasible local arrangement, an explained purpose and an agreed result-review process 00:17:40.936 --> 00:17:43.794 are components of care, not administrative extras. 00:17:44.050 --> 00:17:46.283 Carry the kidney story into the heart story. 00:17:46.596 --> 00:17:49.668 The summary passed to the next clinician should include the kidney measurements 00:17:49.881 --> 00:17:55.598 and dates, current treatment and tolerance, cardiovascular conditions, the unresolved issue and 00:17:55.641 --> 00:18:00.013 who is acting next. Include reproductive history when clinically relevant, but do 00:18:00.056 --> 00:18:02.441 not allow it to crowd out today's priorities. 00:18:02.779 --> 00:18:07.301 This is the distinctive HEART RESERVE connection: women's histories stay visible while 00:18:07.344 --> 00:18:10.629 care becomes specific, coordinated and actionable. 00:18:10.928 --> 00:18:14.170 Here is the decision. Which element is most important to add to 00:18:14.213 --> 00:18:17.295 Carol’s pending referral? Pause here if you would like a moment to 00:18:17.338 --> 00:18:20.965 think it through. The best next step in this case is: An 00:18:21.008 --> 00:18:24.880 agreed interim care owner, result-review plan and patient contact route. 00:18:25.084 --> 00:18:29.180 Make clinical responsibility explicit until an accepted handoff occurs. 00:18:29.607 --> 00:18:33.383 This is the activity’s proposed application of guideline-based follow-up. 00:18:33.660 --> 00:18:35.801 Here is what to carry into the next visit. 00:18:36.064 --> 00:18:39.008 Check the safety result before starting or changing therapy. 00:18:39.264 --> 00:18:42.891 Record test, date, reviewer and patient contact route. 00:18:43.147 --> 00:18:46.625 Confirm referral acceptance and retain interim responsibility. 00:18:47.211 --> 00:18:50.795 Before you go, bring the three cases back to one question: what 00:18:50.838 --> 00:18:52.630 will you do differently at the next visit? 00:18:53.014 --> 00:18:57.067 Use both kidney measures, match evidence to the patient, and treat monitoring 00:18:57.195 --> 00:18:58.938 and follow-up as part of the therapy. 00:18:59.102 --> 00:19:03.753 You’ll find the source references, transcript and clinical resources beside this episode. 00:19:04.137 --> 00:19:07.550 To record your answers and complete the learning activity, return to the 00:19:07.593 --> 00:19:10.333 activity page for the questions and brief evaluation. 00:19:10.683 --> 00:19:12.880 This has been HEART RESERVE Clinical Conversations. 00:19:13.200 --> 00:19:15.633 I’m Lisa Zahakos. Thank you for listening.